Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATX-101 for reduction of submental fat
ACTRN12607000626460Phase 2Not yet recruiting
- Sponsor
- Kythera Biopharmaceuticals
- Start
- Mar 2008
- Modality
- Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised trial of ATX101 in submental fat (6 arms), sponsored by Kythera Biopharmaceuticals. Primary endpoint: Safety and tolerability of ATX-101 injections relative to placebo. Planned start Mar 2008; status: not yet recruiting.
02
Drugs
ATX101
03
Conditions
submental fat
Beyond the preview
Go deeper on ACTRN12607000626460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000626460.